0.6399
price up icon5.61%   0.034
after-market 시간 외 거래: .63 -0.0099 -1.55%
loading

Athira Pharma Inc 주식(ATHA)의 최신 뉴스

pulisher
Nov 04, 2024

Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360

Nov 04, 2024
pulisher
Nov 04, 2024

US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St

Nov 04, 2024
pulisher
Oct 31, 2024

Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com

Oct 31, 2024
pulisher
Oct 26, 2024

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN

Oct 26, 2024
pulisher
Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan

Oct 22, 2024
pulisher
Oct 18, 2024

Athira Pharma faces Nasdaq delisting over share price - Investing.com

Oct 18, 2024
pulisher
Oct 16, 2024

A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News

Oct 16, 2024
pulisher
Oct 07, 2024

A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex

Oct 07, 2024
pulisher
Sep 29, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 27, 2024
pulisher
Sep 26, 2024

Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily

Sep 26, 2024
pulisher
Sep 25, 2024

Check out these key findings about Athira Pharma Inc (ATHA) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Athira Pharma to lay off 70% of workforce - PharmaLive

Sep 23, 2024
pulisher
Sep 23, 2024

Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Athira Pharma to Lay Off 70% of Workforce - BioSpace

Sep 23, 2024
pulisher
Sep 20, 2024

After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech

Sep 20, 2024
pulisher
Sep 20, 2024

Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks

Sep 19, 2024
pulisher
Sep 18, 2024

Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Taking the lead: Athira Pharma Inc (ATHA) - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register

Sep 18, 2024
pulisher
Sep 18, 2024

Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter

Sep 18, 2024
pulisher
Sep 17, 2024

Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to Cut About 70% of Workforce - MarketWatch

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire

Sep 17, 2024
pulisher
Sep 17, 2024

Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient

Sep 17, 2024
pulisher
Sep 17, 2024

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire

Sep 17, 2024
pulisher
Sep 17, 2024

Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex

Sep 17, 2024
pulisher
Sep 16, 2024

Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily

Sep 16, 2024
pulisher
Sep 13, 2024

Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex

Sep 13, 2024
pulisher
Sep 12, 2024

AdPha urges HTA reform - Pharmacy Daily

Sep 12, 2024
pulisher
Sep 12, 2024

Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today

Sep 12, 2024
pulisher
Sep 12, 2024

Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia

Sep 12, 2024
pulisher
Sep 11, 2024

Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News

Sep 11, 2024
pulisher
Sep 11, 2024

Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com

Sep 11, 2024
pulisher
Sep 11, 2024

Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily

Sep 11, 2024
pulisher
Sep 10, 2024

ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Sep 10, 2024
pulisher
Sep 09, 2024

Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily

Sep 09, 2024
pulisher
Sep 09, 2024

Closing Bell Recap: Athira Pharma Inc (ATHA) Ends at 0.54, Reflecting a -3.65 Downturn - The Dwinnex

Sep 09, 2024
pulisher
Sep 07, 2024

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial - Genetic Engineering & Biotechnology News

Sep 07, 2024
pulisher
Sep 06, 2024

Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com Australia

Sep 06, 2024
pulisher
Sep 06, 2024

Athira Pharma (ATHA) Stock Price, News & Analysis - MarketBeat

Sep 06, 2024
pulisher
Sep 05, 2024

Athira Pharma COO Rachel Lenington sells shares worth $1,429 - Investing.com India

Sep 05, 2024
pulisher
Sep 05, 2024

Athira plunges as Alzheimer’s trial setback leads to downgrades - MSN

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma CEO sells over $2.8k in company stock - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma COO Rachel Lenington sells shares worth $1,429 By Investing.com - Investing.com Canada

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma executive sells shares worth $1,429 By Investing.com - Investing.com UK

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma tanks as fosgonimeton misses in Alzheimer’s trial | Pharmaceutical | The Pharmaletter - The Pharma Letter

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral - Defense World

Sep 05, 2024
pulisher
Sep 05, 2024

Athira Pharma (NASDAQ:ATHA) Downgraded to Neutral at Rodman & Renshaw - Defense World

Sep 05, 2024
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
자본화:     |  볼륨(24시간):